Literature DB >> 23297799

Molecular characterization of neoplastic and normal "sister" lymphoblastoid B-cell lines from chronic lymphocytic leukemia.

Anna Lanemo Myhrinder1, Eva Hellqvist, Ann-Charlotte Bergh, Mattias Jansson, Kenneth Nilsson, Per Hultman, Jon Jonasson, Anne Mette Buhl, Lone Bredo Pedersen, Jesper Jurlander, Eva Klein, Nicole Weit, Marco Herling, Richard Rosenquist, Anders Rosén.   

Abstract

Chronic lymphocytic leukemia (CLL) B-cells resemble self-renewing CD5 + B-cells carrying auto/xeno-antigen-reactive B-cell receptors (BCRs) and multiple innate pattern-recognition receptors, such as Toll-like receptors and scavenger receptors. Integration of signals from BCRs with multiple surface membrane receptors determines whether the cells will be proliferating, anergic or apoptotic. To better understand the role of antigen in leukemogenesis, CLL cell lines producing monoclonal antibodies (mAbs) will facilitate structural analysis of antigens and supply DNA for genetic studies. We present here a comprehensive genotypic and phenotypic characterization of available CLL and normal B-cell-derived lymphoblastoid cell lines (LCLs) from the same individuals (n = 17). Authenticity and verification studies of CLL-patient origin were done by IGHV sequencing, fluorescence in situ hybridization (FISH) and DNA/short tandem repeat (STR) fingerprinting. Innate B-cell features, i.e. natural Ab production and CD5 receptors, were present in most CLL cell lines, but in none of the normal LCLs. This panel of immortalized CLL-derived cell lines is a valuable reference representing a renewable source of authentic Abs and DNA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23297799     DOI: 10.3109/10428194.2013.764418

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.

Authors:  E Vasyutina; J M Boucas; J Bloehdorn; C Aszyk; G Crispatzu; M Stiefelhagen; A Breuer; P Mayer; C Lengerke; H Döhner; D Beutner; A Rosenwald; S Stilgenbauer; M Hallek; A Benner; M Herling
Journal:  Leukemia       Date:  2015-05-04       Impact factor: 11.528

2.  Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.

Authors:  Nisar A Amin; Sriram Balasubramanian; Kamlai Saiya-Cork; Kerby Shedden; Nan Hu; Sami N Malek
Journal:  Clin Cancer Res       Date:  2016-08-17       Impact factor: 12.531

3.  Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.

Authors:  Andreas Agathangelidis; Lydia Scarfò; Federica Barbaglio; Benedetta Apollonio; Maria Teresa Sabrina Bertilaccio; Pamela Ranghetti; Maurilio Ponzoni; Gabriella Leone; Valeria De Pascali; Lorenza Pecciarini; Paolo Ghia; Federico Caligaris-Cappio; Cristina Scielzo
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

4.  Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden.

Authors:  Christian Prinz; Elena Vasyutina; Gregor Lohmann; Alexandra Schrader; Steffen Romanski; Christoph Hirschhäuser; Petra Mayer; Corazon Frias; Carmen D Herling; Michael Hallek; Hans-Günther Schmalz; Aram Prokop; Dimitrios Mougiakakos; Marco Herling
Journal:  Mol Cancer       Date:  2015-06-04       Impact factor: 27.401

5.  Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.

Authors:  Lu Qian Wang; Kwan Yeung Wong; Anders Rosèn; Chor Sang Chim
Journal:  Oncotarget       Date:  2015-12-29

6.  Different expression levels of glycans on leukemic cells-a novel screening method with molecularly imprinted polymers (MIP) targeting sialic acid.

Authors:  Zahra El-Schich; Mohammad Abdullah; Sudhirkumar Shinde; Nishtman Dizeyi; Anders Rosén; Börje Sellergren; Anette Gjörloff Wingren
Journal:  Tumour Biol       Date:  2016-07-31

7.  Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.

Authors:  Erin Hertlein; Kyle A Beckwith; Gerard Lozanski; Timothy L Chen; William H Towns; Amy J Johnson; Amy Lehman; Amy S Ruppert; Brad Bolon; Leslie Andritsos; Arletta Lozanski; Laura Rassenti; Weiqiang Zhao; Tiina M Jarvinen; Leigha Senter; Carlo M Croce; David E Symer; Albert de la Chapelle; Nyla A Heerema; John C Byrd
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

8.  The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia.

Authors:  Eahsan Rasul; Daniel Salamon; Noemi Nagy; Benjamin Leveau; Ferenc Banati; Kalman Szenthe; Anita Koroknai; Janos Minarovits; George Klein; Eva Klein
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

9.  Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia.

Authors:  Lu Qian Wang; Kwan Yeung Wong; Zhen Hai Li; Chor Sang Chim
Journal:  Oncotarget       Date:  2016-12-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.